Furthermore, to convert tumor PD-L1 to a ligand that transmits CD28 and 4-1BB costimulatory signals to effector T cells, we generated another combinatorial antigen receptor, PD-1-CD28-4-1BB activating chimeric receptor (PD1ACR). Here, TNFRSF9 is linked to neoplasm.